Black Diamond Therapeutics (BDTX) Metrics: History & Chart

Black Diamond Therapeutics, Inc.(BDTX)

Biotechnology · Cambridge, MA

$1.80-0.15 (-7.47%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Cambridge, MA

21 employees

www.blackdiamondtherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark A. Velleca

View full financials

Third-Party DCF Estimate (FMP)	$10.87
Price Gap vs Third-Party Estimate	+460.28%

7D Total Return	+6.01%
30D Total Return	-8.49%
YTD Total Return	-20.16%
1Y Total Return	-50.13%
3Y Total Return	-23.02%
5Y Total Return	-75.41%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-20.16%
2025	+13.55%
2024	-23.84%
2023	+56.11%
2022	-66.23%
2021	-83.37%
2020

CAGR TTM	-49.96%
CAGR 3Y	-8.35%
CAGR 5Y	-24.47%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	7.16
PE Ratio Avg TTM	10.99
PE Ratio Avg 3Y	10.99
Current VS TTM Avg	-34.83%
Current VS 3Y Avg	-34.83%
Current VS 5Y Avg	-34.83%

All Metrics

BDTX Valuation Metrics

BDTX Stock Price Metrics

BDTX Dividend Metrics

BDTX Growth Rate Metrics

BDTX Discounted Cash Flow Metrics

BDTX Returns By Period

BDTX Yearly Returns

BDTX Average Annual Returns By Period (CAGR)

BDTX Revenue Metrics

BDTX PE Ratio Metrics

BDTX PS Ratio Metrics

BDTX PB Ratio Metrics

BDTX Price to Free Cash Flow Ratio Metrics

BDTX Debt to Equity Ratio Metrics

BDTX PEG Ratio Metrics

BDTX FCF Yield

BDTX Earnings Yield

BDTX EBITDA Yield

BDTX OCF Yield

BDTX EV/EBIT Ratio Metrics

BDTX EV/EBITDA Ratio Metrics

BDTX EV/Assets Ratio Metrics

BDTX EV/Sales Ratio Metrics

BDTX Current Ratio Metrics

BDTX Quick Ratio Metrics

BDTX ROIC Metrics

BDTX Return on Assets Metrics

BDTX Return on Equity Metrics

BDTX Net Profit Margin Metrics

BDTX Gross Profit Margin Metrics

BDTX Tax Rate Metrics

PS Ratio	2.22
PS Ratio Avg TTM	2.29
PS Ratio Avg 3Y	2.29
Current VS TTM Avg	-3.16%
Current VS 3Y Avg	-3.16%
Current VS 5Y Avg	-3.16%

PB Ratio	1.16
PB Ratio Avg TTM	1.25
PB Ratio Avg 3Y	1.37
Current VS TTM Avg	-6.92%
Current VS 3Y Avg	-15.44%
Current VS 5Y Avg	+4.06%

PFCF Ratio	5.24
PFCF Ratio Avg TTM	8.08
PFCF Ratio Avg 3Y	8.08
Current VS TTM Avg	-35.16%
Current VS 3Y Avg	-35.16%
Current VS 5Y Avg	-35.16%

Debt/Equity Ratio	0.18
Debt/Equity Ratio Avg TTM	0.17
Debt/Equity Ratio Avg 3Y	0.21
Current VS TTM Avg	+6.67%
Current VS 3Y Avg	-13.96%
Current VS 5Y Avg	-9.38%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	19.07%
FCF Yield Avg TTM	13.79%
FCF Yield Avg 3Y	13.79%
Current VS TTM Avg	+38.31%
Current VS 3Y Avg	+38.31%
Current VS 5Y Avg	+38.31%

Earnings Yield	13.97%
Earnings Yield Avg TTM	9.36%
Earnings Yield Avg 3Y	9.36%
Current VS TTM Avg	+49.23%
Current VS 3Y Avg	+49.23%
Current VS 5Y Avg	+49.23%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	12.22
Ev/Ebit Ratio Avg TTM	21.29
Ev/Ebit Ratio Avg 3Y	21.29
Current VS TTM Avg	-42.61%
Current VS 3Y Avg	-42.61%
Current VS 5Y Avg	-42.61%

Ev/Ebitda Ratio	11.92
Ev/Ebitda Ratio Avg TTM	20.17
Ev/Ebitda Ratio Avg 3Y	20.17
Current VS TTM Avg	-40.90%
Current VS 3Y Avg	-40.90%
Current VS 5Y Avg	-40.90%

Ev/Assets Ratio	0.87
Ev/Assets Ratio Avg TTM	0.93
Ev/Assets Ratio Avg 3Y	0.97
Current VS TTM Avg	-6.66%
Current VS 3Y Avg	-9.89%
Current VS 5Y Avg	+16.48%

Ev/Sales Ratio	2.19
Ev/Sales Ratio Avg TTM	1.95
Ev/Sales Ratio Avg 3Y	1.95
Current VS TTM Avg	+12.16%
Current VS 3Y Avg	+12.16%
Current VS 5Y Avg	+12.16%

Current Ratio	7.28
Current Ratio Avg TTM	8.37
Current Ratio Avg 3Y	7.60
Current VS TTM Avg	-12.95%
Current VS 3Y Avg	-4.11%
Current VS 5Y Avg	-10.40%

Quick Ratio	7.28
Quick Ratio Avg TTM	8.37
Quick Ratio Avg 3Y	7.60
Current VS TTM Avg	-12.95%
Current VS 3Y Avg	-4.11%
Current VS 5Y Avg	-10.40%

ROIC	(47.54%)
ROIC Avg 3Y	(42.43%)
ROIC Avg 5Y	(61.13%)
Current VS 3Y Avg	-12.03%
Current VS 5Y Avg	+22.23%
Current VS 10Y Avg	-16.76%

ROA	(34.04%)
ROA Avg TTM	(7.40%)
ROA Avg 3Y	(10.75%)
Current VS TTM Avg	-359.69%
Current VS 3Y Avg	-216.74%
Current VS 5Y Avg	-183.09%

ROE	(44.29%)
ROE Avg TTM	(7.57%)
ROE Avg 3Y	(44.30%)
Current VS TTM Avg	-485.03%
Current VS 3Y Avg	+0.03%
Current VS 5Y Avg	+31.65%

Net Profit Margin	31.95%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	99.54%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A